MERTK

Therapeutic Solutions International Announces Positive Preclinical Results Using JadiCells™ in Animal Model of Chronic Obstructive Pulmonary Failure (COPD)

Retrieved on: 
Monday, August 23, 2021
Company, Research, B cell, Animal, MERTK, Cell, Business development, ICU, IND, Stem cell, Survival rate, Patient, CEO, ELK, OTC Markets Group, Bone marrow, COVID-19, Patent, Pharmaceutical industry

Superior reduction in lung damage was observed in animals receiving JadiCells as compared to other clinically used stem cells such as adipose and bone marrow derived mesenchymal stem cells.

Key Points: 
  • Superior reduction in lung damage was observed in animals receiving JadiCells as compared to other clinically used stem cells such as adipose and bone marrow derived mesenchymal stem cells.
  • "The potent anti-inflammatory and regenerative effects of the JadiCells have been demonstrated in a variety of in vitro and in vivo settings.
  • "We at Therapeutic Solutions International are committed to cautiously exploring this new potential avenue of research in order to advance science for patients and our shareholders."
  • Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases.

BeiGene Presents Clinical Data on Sitravatinib in Combination with Tislelizumab at the AACR Annual Meeting 2021

Retrieved on: 
Sunday, April 11, 2021
Oncology, Health, FDA, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Branches of biology, Tyrosine kinase receptors, Cell signaling, AXL receptor tyrosine kinase, MERTK, Bruton's tyrosine kinase, Tumor microenvironment, Zanubrutinib, Vascular endothelial growth factor, TME, TYRO3, Programmed cell death protein 1, Sitravatinib, Tislelizumab, the Tislelizumab Clinical Program, BeiGene

At the time of data cutoff, 16 patients (64%) remained on study treatment.

Key Points: 
  • At the time of data cutoff, 16 patients (64%) remained on study treatment.
  • The combination of sitravatinib and tislelizumab was generally well tolerated and showed promising antitumor activity among patients with advanced PROC, including those who were heavily pretreated.
  • Sitravatinib targets the VEGFR and TAM (TYRO3, AXL, MERTK) receptor families, which are implicated in orchestrating an immunosuppressive tumor microenvironment (TME).
  • We currently market two internally discovered oncology medicines: BTK inhibitor BRUKINSA\xc2\xae (zanubrutinib) in the United States and China, and anti-PD-1 antibody tislelizumab in China.

2020 Tyrosine Protein Kinase Mer Pipeline Review, H1 - ResearchAndMarkets.com

Retrieved on: 
Friday, March 27, 2020
Pharmaceutical, Health, Clinical trials, Enzymes, Tyrosine kinase receptors, MERTK, Tyrosine kinase, Mer, Receptor tyrosine kinase, Protein kinase, FER, Oncogene, AXL receptor tyrosine kinase, ABL, Enzymes, Tyrosine kinase receptors, MERTK, Tyrosine kinase, Mer, Receptor tyrosine kinase, Protein kinase, FER, Oncogene, AXL receptor tyrosine kinase, ABL

The "Tyrosine Protein Kinase Mer - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Tyrosine Protein Kinase Mer - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) pipeline Target constitutes close to 19 molecules.
  • This report outlays comprehensive information on the Tyrosine Protein Kinase Mer targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • It also reviews key players involved in Tyrosine Protein Kinase Mer targeted therapeutics development with respective active and dormant or discontinued projects.

Global Tyrosine Protein Kinase Mer Pipeline Overview 2020 with Analysis by Indication, Stage of Development, Mechanism of Action, Route of Administration and Molecule Type

Retrieved on: 
Thursday, March 26, 2020
Enzymes, Tyrosine kinase receptors, Tyrosine kinases, MERTK, Tyrosine kinase, Mer, Receptor tyrosine kinase, Protein kinase, FER, ABL, Book:Bc3sigtrann

DUBLIN, March 26, 2020 /PRNewswire/ -- The "Tyrosine Protein Kinase Mer - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 26, 2020 /PRNewswire/ -- The "Tyrosine Protein Kinase Mer - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) pipeline Target constitutes close to 19 molecules.
  • This report outlays comprehensive information on the Tyrosine Protein Kinase Mer targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • It also reviews key players involved in Tyrosine Protein Kinase Mer targeted therapeutics development with respective active and dormant or discontinued projects.

Rgenix Presents Pre-Clinical Data on RGX-019 at the 2019 AACR Annual Meeting

Retrieved on: 
Wednesday, April 3, 2019
Health, Alternative medicine, Biotechnology, Clinical trials, Oncology, Pharmaceutical, Radiology, Other Health, Research, Other Science, Science, Tyrosine kinase receptors, AXL receptor tyrosine kinase, MERTK, Tyrosine kinase, Receptor tyrosine kinase

RGX-019 is a humanized monoclonal antibody that selectively targets MERTK, a receptor tyrosine kinase of the TYRO3/AXL/MERTK (TAM) family.

Key Points: 
  • RGX-019 is a humanized monoclonal antibody that selectively targets MERTK, a receptor tyrosine kinase of the TYRO3/AXL/MERTK (TAM) family.
  • Activation of MERTK on cancer cells via ligand binding activates several tumor-promoting signaling pathways, stimulating tumor proliferation, migration and angiogenesis, and decreasing apoptosis and chemosensitivity.
  • RGX-019is an investigational drug candidate and a humanized monoclonal antibody that targets MERTK being developed by Rgenix for the treatment of advanced cancer.
  • Rgenix in-licensed RGX-019 related antibody intellectual property from Rockefeller University as part of a world-wide exclusive licensing agreement.